Member Info for B2HS2L

You can afford beer?

Have you maxed out your ISA?

No other explanation adds up, 170k or no.

Wyndrum

29 question marks in nine posts today, and we still have this evening to go.

I don't think you've touched on LFT's yet.

This is FUD, repeated FUD and FUD redefined all in one day.

It's not an attempt at keeping a balanced point of view on this board.

Not a good look, but what do we poor sods know or care any more.

Evaporate, - not difficult for one so full of hot air.

Wouldn't CC count R&D spotlight interviews as being sources of information for all interested parties.

That's what she started beginning 27.03.2024.

8 so far, an average of one every 1.5 months ish.

There's way more info in a spotlight than in a tweet.

Most have splurged an awful lot of money on ADC's already (and the additional R&D development costs) within the last 5 years, so financially they will be feeling really sick if they decide they will be one of the bidders for PDC developing Avacta.

PDC's we are told are cheaper, easier and faster to develop than ADC's, so those still developing ADC's will be disadvantaged.

When, not If, PDC's supersede ADC's, then you have to own the Avacta IP, which locks out PDC development for other BP's.

I await a reply to a note to consilium asking whether the company had a crown jewels defence.

If phase 1b ticks all the boxes, we should see BP unwilling to wait longer (with Avacta's R&D team so small and slow).

They will want to bid and crack on.

Recent R&D spotlight 8

Ruairidh Edwards - translational scientist.

"With the AVA6000 study, we used empirical analysis to try and determine which patients we were treating in the clinic.

With AVA6103, we're using AI to really understand and characterize the patients that we want to treat."

+++

Can't see why Empirical analysis would continue to be used for patient selection in AVA6000 P1b if we are signed up to Tempus.

This should provide much more targeted phase 1b data outcomes.

Avacta PLC investor webinar video – Turner Pope – 10.04.2024

https://www.turnerpope.com/webinar-avacta-apr24/ From 26 mins = Q/A session.

Q4 What is the longest a single patient has been on drug to date?

A4 The patient with the first partial response, a patient with Undifferentiated Pleomorphic Sarcoma had their first baseline scan in February 2023 last year, that's when he started on the trial, and the latest follow up scan was in January 2024.

The patient still on trial with a reduction in tumour size of 74% (as of January 2024).

And, very much reduced side effects over that one year period whilst he's been on the study.

That patient can also continue to be treated because of the low systemic exposure that that patient is receiving to Doxorubicin.

We know that from the PK measurements, and that's precisely what precision was designed to achieve.

++++

RNS 30 September 2024

Interim Results

AVA6000 Phase 1a Clinical trial data summary

Efficacy data

o A partial response in a 60-year-old male with undifferentiated pleomorphic sarcoma (UPS) with one prior line of therapy in the metastatic setting (reported in April 2024 at the AACR conference).

This patient remains on study at the time of the data cutoff (19.08.2024) with a duration of response of >55 weeks.

*note tumour size not stated.

My reference document so far is

https://www.investegate.co.uk/announcement/rns/avacta-group--avct/private-cb-and-abb-launch/7352195

Proposed placing to raise approximately £5.0 million by way of an accelerated bookbuild

Open offer to raise up to approximately £2.0 million

Offering of convertible bonds in aggregate principal amount of £55.0 million

APPENDIX II - SUMMARY OF PRINCIPAL TERMS FOR THE CONVERTIBLE BONDS

If anyone can provide a reference I'd appreciate it.

I'm not understanding 'convert the entire CLN to additional shares' Ice.

If that's an option, I'm not finding it at present.

The timing of a hostile bid too early would mean Avacta would not have developed the precision platform, AVA6000, AVA6103 and AVA7100 to the level they intend before they are ready to listen to offers.

A hostile bid pre AVA6000 P1b results publication would be bad.

A predator might get the opportunity to appeal to predominantly private shareholders to purchase the company cheaply, but might not bother if a CJD were already in place.

As I say I can't find evidence of one.

After a hostile bid, other companies might join in to create an auction, but the starting price would be disappointingly low for an 'unfinished project'.

Found this recently and thought in Avacta's new circumstances, the BoD should be ensuring we have this defence.

Hostile takeover bid - https://www.investopedia.com/terms/h/hostiletakeover.asp

Crown jewel defence

In a crown jewel defence, a provision of the company's bylaws requires the sale of the most valuable assets if there is a hostile takeover, thereby making it less attractive as a takeover opportunity.

This is often considered one of the last lines of defence.

29.04.2003 :

https://avacta.com/wp-content/uploads/2023/02/Avacta-Group-plc-Articles-of-Association-22-01-2010.pdf

Dated 2003, file name contains January 2010.

I've checked this document, but don't believe it contains a CJD.

Is a newer version available, or perhaps I'm looking in the wrong document.

Https://www.fiercebiotech.com/biotech/pfizer-takes-12b-hit-after-assessing-prospects-seagen-adcs

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. The Big Pharma disclosed the blow alongside a $200 million charge linked to another ADC.

The $1 billion charge is tied to B7H4V, an ADC that Pfizer acquired in its takeover of Seagen late in 2023. Seagen began a phase 1 trial of the ADC in people with advanced solid tumors in 2022. Recruitment stopped in September 2023 but resumed again the next month. Seagen stopped enrollment again in December 2024.

Now, Pfizer has revealed the latest halt is permanent.

“We have made a business decision to discontinue the felmetatug vedotin (FV) development program based on clinical data generated to date indicating that FV is unlikely to achieve a meaningful improvement over standard-of-care chemotherapy in patients with advanced solid tumors, including triple-negative breast cancer," a Pfizer spokesperson said

+++

Timber!!

* What's interesting about this one is on the left hand side where we stop treatment and we still continue with these complete regressions, we're seeing that in the clinic with AVA6000.

* Patients with salivary gland cancer who have essentially stopped treatment due to reaching the max level of cycles, they're continuing in these responses.

* Maybe it's a precision thing, something else that we're all gonna have to figure out.

Then we hear from Rory - Ruairidh Edwards - translational scientist.

Everybody's been waiting for this Tempus data. (09:20 on video)

With the AVA6000 study, we used empirical analysis to try and determine which patients we were treating in the clinic.

With AVA6103, we're using AI to really understand and characterize the patients that we want to treat.

+++

Empirical analysis was used in the AVA6000 phase 1a because there was no Tempus data available, the deal providing access to AI data had not been signed.

With AVA6000 phase 1b kicking off, I believe Avacta will use Tempus data to "really understand and characterize the patients that we want to treat".

They've paid for Tempus data now, why retain empirical methods of patient selection in AVA6000.

This should provide more promising phase 1b data outcomes, and now there should be many more potential trial patients after the success of Avacta phase 1a trials.

+++

"where we stop treatment and we still continue with these complete regressions, we're seeing that in the clinic with AVA6000".

That should be an outcome of using AI to choose patients perhaps.

Https://www.astrazeneca.com/content/dam/az/Investor_Relations/events/ID/Oncology-presentation.pdf

Astrazeneca Oncology presentation dated 23/05/2024

Food for thought, apologies if posted before.

Yes, though at first glance I thought it was a comment made about Avacta prospects.

Sorry to disturb your deramping efforts wyndrum, I'll continue ignoring your posts.

Wyndrum

Posts: 10,503

Price: 47.00

No Opinion

RE: Worst case scenario based on data collected now. Today 09:46

"Looks like its worth a punt now."

++++

YOU ALL HEARD IT HERE FIRST

Avacta posters therefore have an expectation henceforth that wyndrum's posts aren't exceptionally boring, nit-picking, bearish, and contain endless questions, now that prospects for Avacta are 'WORTH A PUNT'.

++++

You'll still have to buck up to be useless.

H4 - please see RNS 24.10.2024

Bystander effect is in use in ADC development,

but please wordsearch 'bystander' for wording used within an Avacta RNS.

20.01.2025 - apologies if posted already

https://www.onclive.com/view/ava6000-elicits-clinically-meaningful-tumor-shrinkage-in-salivary-gland-cancer

Key Takeaways

* AVA6000 showed clinically meaningful tumor shrinkage in FAP-positive salivary gland cancer, with a 90% disease control rate in the trial cohort.

* The phase 1a trial demonstrated a favorable safety profile, reducing severe hematologic and cardiac toxicities compared to conventional doxorubicin.

* Positive results have led to phase 1b expansion cohorts for triple-negative breast cancer, soft tissue sarcoma, and salivary gland cancer.

* The trial continues to explore AVA6000's potential in less heavily pretreated patients, aiming to address high unmet needs in these disease settings.

Note the list of Strategic Alliance Partners - getting the word out there.

https://www.onclive.com/sap-partner

Any FDA recognition of Avacta projects (particularly SGC), should alert the industry and industry journalists, to the content of the latest R&D spotlight video, underlining the AVA6103 & AVA6000 claims within.

The fact the video was launched on 29th Jan, and caused very little interest is truly amazing.

Vacta Group PLC

04 February 2025

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Appointment of Joint Broker

LONDON and PHILADELPHIA - February 4, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Panmure Liberum Limited ("Panmure Liberum") as its joint broker with immediate effect. Panmure Liberum will work alongside Peel Hunt, the Company's Nominated Adviser and existing corporate broker.

Thompi

Do you think Avacta is vulnerable to a hostile bid, where an offer of sp multiples is aimed at attracting support from PI's, and not as others have stated, from the value of benchmark deals elsewhere in the market?

(A high percentage of Avacta shares are owned by PI's).

++++

"we stop treatment and we still continue with these complete regressions"

CC ..."maybe it’s a pre|CISION® thing, something we are all going to have to figure out ..”.

"100% tumor clearance in 4/6 animals, no recurrence".

+++

We can expect these comments to proliferate in future if further evidence of brilliant trial results emanate from R&D.

One or two big pharma may want to make an early bid, because they know they could be financially outgunned by others, so it's an early bid appealing to PI's or nothing.

The longer BP wait the more certain that efficacy evidence is published, and waiting until further results become available is not a good thing if finances are dictating an early bid strategy.

So for me, a hostile bid could arrive, - only long odds available, - since the prize is an opportunity to grab an ADC beating drug delivery platform.